COLL

Collegium Pharmaceutical Stock Analysis

AI Rating

Neutral
  • Quality8/10
  • Growth 1/10
  • Value 4/10
Collegium Pharmaceutical sales and earnings growth
COLL Growth
Low
  • Revenue Y/Y 18.87%
  • EPS Y/Y 73.53%
  • FCF Y/Y 67.80%
Collegium Pharmaceutical gross and profit margin trends
COLL Profitability
Great
  • Gross margin 60.70%
  • EPS margin 9.40%
  • ROIC 5Y 23.19%
Collegium Pharmaceutical net debt vs free cash flow
COLL Risk
Fair
  • Debt / Equity 2.6
  • Debt / FCF 1.6
  • Interest coverage 2.4

Collegium Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Fair risk rating.

↗ More Drug Manufacturers - Specialty & Generic stocks